GGrantIndex
← Leaderboards

Meredith Gregory-Ksander

Massachusetts Eye And Ear Infirmary

$8,880,864
Attributed
$12,736,853
Total exposure
10
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.5M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$12,736,853 · 10

By mechanism

R01$10,880,246 · 6
R21$1,058,667 · 2
T32$662,188 · 1
F32$135,752 · 1

Most similar at Massachusetts Eye And Ear Infirmary

Same institution · by research overlap

Others in their field

Top investigators on “Prevent

Research focus

PreventInflammationBlindnessTissuesCellsSitePathogenesisMediatingRetinaImmuneCell TypeApoptosisInflammatoryTumor Necrosis Factor Ligand Superfamily Member 6MembraneCd95 AntigensCell DeathRetinal Ganglion CellsPlayGlaucomaCleaved CellIn VitroCytokineLead

Grant awards (34)

In vivo epigenetic reprogramming of retinal ganglion cells in aging mice with glaucoma$679,159
R01 · FY2025 · EY · contact PI
Fas Ligand Cleavage regulates ocular homeostasis and glaucoma$588,524
R01 · FY2025 · EY · contact PI
Training Program in the Molecular Bases of Eye Disease$241,593
T32 · FY2025 · EY
Fas Ligand Cleavage regulates ocular homeostasis and glaucoma$600,249
R01 · FY2024 · EY · contact PI
Regulation of the neuroinflammatory response in autoimmune uveitis$425,000
R01 · FY2024 · EY
Training Program in the Molecular Bases of Eye Disease$186,846
T32 · FY2024 · EY
Fas Ligand Cleavage regulates ocular homeostasis and glaucoma$600,249
R01 · FY2023 · EY · contact PI
Regulation of the neuroinflammatory response in autoimmune uveitis$425,000
R01 · FY2023 · EY
Training Program in the Molecular Bases of Eye Disease$233,749
T32 · FY2023 · EY
Fas Ligand Cleavage regulates ocular homeostasis and glaucoma$43,575
R01 · FY2023 · EY · contact PI
Fas Ligand Cleavage regulates ocular homeostasis and glaucoma$619,633
R01 · FY2022 · EY · contact PI
Regulation of the neuroinflammatory response in autoimmune uveitis$412,250
R01 · FY2022 · EY
Regulation of the neuroinflammatory response in autoimmune uveitis$425,000
R01 · FY2021 · EY
Uncoupling caspase 8-mediated-apotosis from caspase 8-mediated-inflammation in glaucoma.$246,250
R21 · FY2020 · EY · contact PI
Uncoupling caspase 8-mediated-apotosis from caspase 8-mediated-inflammation in glaucoma.$295,500
R21 · FY2019 · EY · contact PI
Neurotoxicity and neuroprotection in the DBA/2J spontaneous model of glaucoma$475,300
R01 · FY2015 · EY · contact PI
Neurotoxicity and neuroprotection in the DBA/2J spontaneous model of glaucoma$475,300
R01 · FY2014 · EY · contact PI
Neurotoxicity and neuroprotection in the DBA/2J spontaneous model of glaucoma$460,750
R01 · FY2013 · EY · contact PI
Regulation of vascular leakage in age related macular degeneration$216,709
R21 · FY2013 · EY · contact PI
Neurotoxicity and neuroprotection in the DBA/2J spontaneous model of glaucoma$485,000
R01 · FY2012 · EY · contact PI
Role of Toxins in Endophthalmitis$416,988
R01 · FY2012 · EY
Regulation of vascular leakage in age related macular degeneration$300,208
R21 · FY2012 · EY · contact PI
Role of Toxins in Endophthalmitis$416,988
R01 · FY2011 · EY
Role of Toxins in Endophthalmitis$434,676
R01 · FY2010 · EY
Role of Toxins in Endophthalmitis$481,250
R01 · FY2009 · EY
Soluble Fas Ligand and Ocular Immune Privilege$380,644
R01 · FY2009 · EY · contact PI
Role of Toxins in Endophthalmitis$481,250
R01 · FY2008 · EY
Soluble Fas Ligand and Ocular Immune Privilege$373,029
R01 · FY2008 · EY · contact PI
Soluble Fas Ligand and Ocular Immune Privilege$380,644
R01 · FY2007 · EY · contact PI
Soluble Fas Ligand and Ocular Immune Privilege$382,788
R01 · FY2006 · EY · contact PI
Soluble Fas Ligand and Ocular Immune Privilege$417,000
R01 · FY2005 · EY
Fas Ligand Regulation of Ocular Innate Immunity$49,364
F32 · FY2003 · EY
Fas Ligand Regulation of Ocular Innate Immunity$46,192
F32 · FY2002 · EY
Fas Ligand Regulation of Ocular Innate Immunity$40,196
F32 · FY2001 · EY